Image

Evaluating Treatment Strategies for p53 Mutant Oral Cancer and Oral Cancer Precursors

Evaluating Treatment Strategies for p53 Mutant Oral Cancer and Oral Cancer Precursors

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The goal of this clinical trial is to optimize treatment strategies for patients with p53-mutant oral epithelial dysplasia (OED) and early-stage oral squamous cell carcinoma (OSCC). The main question it aims to answer is what the most optimal treatment is at each diagnostic stage. It is hypothesized that lesions with p53-abnormal low-grade dysplasia (LGD) without surgical intervention will progress to high-grade dysplasia (HGD) or SCC in 4 years. It is also predicted that a clear p53 and severe/CIS excision margins in patients with p53-abnormal HGD will reduce the progression to invasive SCC, compared to clear severe/CIS margins, within 4 years. Finally, it is thought that patients with p53-abnormal cT1N0 and DOI\<4mm receiving an END will have improved disease free and overall survival. This research will elucidate whether or not these hypotheses are correct.

Participants in each diagnostic cohort will be assigned to one of two different treatment options, listed below:

Cohort 1:

  1. No intervention, observation only B) Surgical excision with clear margins

Cohort 2:

  1. Surgical excision with clear severe/CIS margins B) Surgical excision with clear severe/CIS and p53 margins

Cohort 3:

  1. Surgical excision and elective neck dissection (END) B) Surgical excision and close follow-up, only salvage ND if development of nodal disease

Eligibility

Inclusion Criteria:

  • Adults age 18 or over
  • No history of head and neck radiation
  • p53-abnormal IHC patterns (surrogate marker for TP53 mutation)

Cohort 1:

  • Biopsy-confirmed mild/moderate dysplasia

Cohort 2:

  • Biopsy-confirmed severe dysplasia or CIS

Cohort 3:

  • T1 SCC with depth of Invasion (DOI) \<4mm
  • Clinically and radiologically node-negative (confirmed by contrast-enhanced CT)

Exclusion Criteria:

  • Immunocompromised status
  • Lesions greater than 3 cm
  • Presence of Proliferative Verrucous Leukoplakia

Cohort 1:

  • Had prior treatment for oral premalignant lesions

Cohort 2:

  • Presence of invasive SCC on initial biopsy

Cohort 3:

  • Positive nodes on contrast-enhanced CT
  • DOI \>= 4mm

Study details
    Oral Epithelial Dysplasia (OED)
    Oral Squamous Cell Carcinoma (SCC)

NCT07090070

University of British Columbia

12 September 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.